Stocks of Tenaya Therapeutics Inc. (NASDAQ:TNYA) traded higher last session on Wall Street, down -1.29% to $2.29.
According to the data, Tenaya Therapeutics Inc. (NASDAQ:TNYA) has 6 analysts covering its stock. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $40.00 and a low of $15.00, we find $21.00. Given the previous closing price of $2.32, this indicates a potential upside of 805.17 percent. TNYA stock price is now 1.31% away from the 50-day moving average and -54.46% away from the 200-day moving average. The market capitalization of the company currently stands at $148.51M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
A total of 0 analysts have issued a hold rating and 6 have given it a buy rating. Brokers who have rated the stock have averaged $24.20 as their price target over the next twelve months.
With the price target of $25, H.C. Wainwright recently initiated with Buy rating for Tenaya Therapeutics Inc. (NASDAQ: TNYA).
In other news, Srivastava Deepak, Director bought 230,769 shares of the company’s stock on Nov 21. The stock was bought for $599,999 at an average price of $2.60. Upon completion of the transaction, the Director now directly owns 372,435 shares in the company, valued at $0.85 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 21, 10% Owner COLUMN GROUP III GP, LP bought 9,615,384 shares of the business’s stock. A total of $24,999,998 was incurred on buying the stock at an average price of $2.60. This leaves the insider owning 9,615,384 shares of the company worth $22.02 million. Insiders disposed of 1,353 shares of company stock worth roughly $3098.37 over the past 1 year. A total of 0.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in TNYA stock. A new stake in Tenaya Therapeutics Inc. shares was purchased by REGENTS OF THE UNIVERSITY OF CALIFORNIA during the first quarter worth $3,725,000. T. ROWE PRICE INVESTMENT MANAGEMENT, INC. invested $3,583,000 in shares of TNYA during the first quarter. In the first quarter, JACOBS LEVY EQUITY MANAGEMENT, INC acquired a new stake in Tenaya Therapeutics Inc. valued at approximately $588,000. RENAISSANCE TECHNOLOGIES LLC acquired a new stake in TNYA for approximately $381,000. MARSHALL WACE, LLP purchased a new stake in TNYA valued at around $203,000 in the second quarter. In total, there are 94 active investors with 55.70% ownership of the company’s stock.
Friday’s opening bell rang with an opening price of $2.3200 for Tenaya Therapeutics Inc. (NASDAQ: TNYA). During the past 12 months, Tenaya Therapeutics Inc. has had a low of $1.64 and a high of $16.17. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 8.90, and a quick ratio of 8.90. The fifty day moving average price for TNYA is $2.2485 and a two-hundred day moving average price translates $4.9807 for the stock.
The latest earnings results from Tenaya Therapeutics Inc. (NASDAQ: TNYA) was released for Jun, 2022.
Tenaya Therapeutics Inc.(TNYA) Company Profile
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
